Introduction
Autoimmune diseases such as juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE) and others are a cause of major morbidity in children, both because of the underlying disease process and currently available therapies. 1, 2 In particular, there is a dire need for new treatment modalities in the subset of patients with severe or refractory disease. 3, 4 Initial evidence that hematopoietic stem cell transplant (HSCT) could be used as therapy for this class of diseases came from incidental reports of cure of autoimmune diseases in patients who were transplanted for malignant diseases. [5] [6] [7] In 1996, the European League Against Rheumatism (EULAR) together with the European Group for Blood and Marrow Transplantation (EBMT) came out with a consensus statement with recommendations as to which patients should be treated in this way and with which regimens. 8 Since then, multiple case reports and trials have been published; however, most of the data are on adult patients receiving autologous transplants. The EBMT Paediatric and Autoimmune Diseases Working Parties recently published a summary of the data in children to date. 9 This mini review critically evaluates the literature thus far, with an emphasis on future directions in the field.
Rationale
The rationale for HSCT in treating autoimmune disease comes first from the incidental findings in patients who underwent HSCT for bone marrow failure or malignant diseases with pre-existing autoimmune diseases. Initial reports of cure of the underlying autoimmune disease after allogeneic 10 or autologous 11 transplant performed for standard indications (reviewed in Hinterberger et al.
12
) led to a search for mechanisms underlying these favorable outcomes. This was followed by recommendations regarding the appropriateness of the use of HSCT up front in the treatment of refractory autoimmune disease. An autologous transplant approach was initially the most intuitive, with the thought that the intense immune suppression induced by the conditioning regimen 'resets' the immune system and allows for a second attempt at self-tolerance as bone marrow precursors seed the thymus once again. 5, [13] [14] [15] This approach was embraced over an allogeneic one because of concerns of higher morbidity and mortality with allogeneic transplantation. It must be noted, however, that even early studies hinted at a strong possibility of failure with this approach, as some patients whose autoimmune disease went into remission early after transplant subsequently relapsed. 16 A vaccination study performed by Brinkman et al. 17 in both children and adults suggests that immune suppression alone, in the setting of autologous HSCT, may not suffice to generate the tolerance needed to cure the autoimmunity.
The transfer of autoimmune disease from HSCT donor to recipient, [18] [19] [20] [21] [22] though potentially caused by reactivation of donor memory cells, 23 speaks to the underlying theory that autoimmune disease may be caused not merely by failed tolerance induction, but also by an underlying abnormality in the stem cell itself. 24 Further evidence of this comes from a report of psoriasis/psoriatic arthritis that relapsed post-HSCT concurrent with increasing host chimerism and then resolved with discontinuation of immune suppression and reversion to donor chimerism; 25 it is also supported by another case report of psoriasis, which had initially resolved post transplant and then relapsed but resolved concurrent with a GVHD flare. 26 In the latter case, the reinduction of immune suppression to treat the GVHD confounds the analysis of whether this is truly a graft vs autoimmunity (GVA) effect or merely a response to standard autoimmune therapies. Further evidence for the ability of unaffected donor-derived stem cells to cure autoimmune disease, or for the ability of allogeneic donor lymphocytes to eliminate host autoreactive ones, is an advantage in relapse-free survival of allogeneic vs autologous SCT in a retrospective comparison between the two in the setting of coexistent hematologic and autoimmune disease. 12 Another reason for the better outcome of allogeneic over autologous grafts in this setting may be traced to the fact that some genetic predispositions for autoimmune disease have been localized to alleles of the MHC. 27 Finally, preclinical models of successful transplantation of genetically manipulated stem cells that cure mice of their predisposition for autoimmunity sow the seeds for another potential way HSCT may be valuable in this setting in the future. 28, 29 On the other hand, the finding that the T cell repertoire in patients who respond to autologous HSCT is initially skewed in favor of suppressive regulatory T cells, that this skewing is thymus dependent, and that there is associated tilting of the autoreactive T cell clones in favor of a Th2 phenotype 30 points to the 'resetting' of the recipient immune system as the most important outcome after HSCT in these patients.
Animal models
As much of the initial data regarding the potential utility of HSCT as frontline therapy for refractory autoimmune disease came from anecdotal reports, animal models have had a major role in advancing our understanding of the basic biology of this approach (reviewed in van Bekkum 31 ). As early as 1974, a murine lupus-like syndrome in the New Zealand Black mouse was found to be transmitted on transfer of bone marrow into lethally irradiated wild-type recipients. 32 It was not long before the transplant of bone marrow from an unaffected wild-type mouse was found to be curative of the syndrome. 33 Experimental (allergic) autoimmune encephalomyelitis, an inducible, oft-used model for multiple sclerosis, has been shown to be preventable by allogeneic more than autologous SCT. [34] [35] [36] This finding further supports the hypothesis mentioned above; autoimmune diseases are caused, at least in part, by intrinsic cellular defects rather than a simple failure of tolerance. 37 Disease models of diabetes have yielded similar results. 38 As noted by others, extrapolation of animal study data to the human context is difficult as most animal studies show that transplantation can prevent rather than treat established autoimmune syndromes. 39 Ikehara's group has reported new methods for achieving infusion of essentially T cell-depleted bone marrow without technical T cell depletion. 40, 41 Despite optimistic results in animal models, it remains to be seen whether the benefit of the GVA effect is lost with this approach. Finally, recent studies have shown that when the bone marrow of mice with EAE is transduced to express self-antigen and then transplanted into syngeneic animals, the disease can be prevented and even cured long term, providing evidence that clonal deletion is the mechanism underlying these effects 42 ( Table 1) .
Experience to date
A Pubmed search of 'pediatric autoimmune disease stem cell transplant' results in only 43 items, 20 of which report or review clinical data on the subject. This paucity of data is only a tip of the iceberg; even published data themselves are difficult to interpret, given the fact that the majority of reports are retrospective reviews, and thus the heterogeneity of conditioning regimens, stem cell harvesting procedures and underlying diseases. Further, most data published on HSCT in autoimmune disease since 1996 focus on adult patients; in the cases where children were included in the study as ascertained from patient characteristics, their outcomes are to a large extent not discernible separately from the outcomes of the overall patient population. Table 2 summarizes the data that have been published over the past 5 years, including both studies that are limited to children and those that include children in the cohorts analyzed. In all, the data reflect a total of 115 patients with a variety of autoimmune conditions. Of these, 68 (59%) sustained CRs and 28 (24%) PRs/transient CRs; 15 patients (13%) showed no response, and there were 6 deaths overall. It is noted that of 8 patients transplanted there was only 1 (12.5%) death in the allo group, and the remaining patients all experienced a CR at follow-up times ranging from 6 months to 6 years; in the auto group, there were 5 (4.5%) deaths, with 66 (62%) CRs, 28 (26%) PRs/ transient CRs, and 15 (14%) did not respond. Rabusin et al. 9 recently published a comprehensive review of the literature on pediatric HSCT in autoimmune disease, to which the reader is referred for a detailed description of each trial. As depicted, the initial reports of HSCT for JIA in particular are encouraging, 43, 45, 46 though reports of a high incidence of macrophage activation syndrome (MAS) early on raised a 'red flag' with regard to intolerable morbidity and mortality in a spectrum of diseases where short-term disease-related mortality is low. 44 The 'incidental' cure of celiac disease in a child receiving a transplant for AML 53 is reminiscent of the early findings in adults. The thymic-dependent role of regulatory T cells reported as part of a pediatric study 30 seems particularly relevant in children whose thymi are still functioning under normal circumstances. 57 This point is particularly significant in the context of HSCT for Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome, a rare but severe multi-system autoimmune disease that results in colitis, failure to thrive, insulin-dependent diabetes mellitus, hypothyroidism, hemolytic anemia and other critical manifestations secondary to mutations in the FOXP3 gene and subsequent dysfunctional CD4 þ CD25 þ FoxP3 þ T-reg activity. 58, 59 Though previous attempts at myeloablative HSCT were met with high mortality rates with a cost that seemed to outweigh their benefit of amelioration of autoimmune symptoms when successful in survivors, 60-63 a recent report of successful transplant after a reducedintensity conditioning regimen in 4 affected children is encouraging. 56 These results support the findings of de Kleer et al., referenced above, with regard to the 'normalization' of regulatory T cell (Treg) activity as a mechanism for the efficacy of HSCT in the autoimmune disease setting in general.
In addition to the results shown above, there have been a few other studies that included a significant number of pediatric cases without referring specifically to their outcomes. A report of 53 patients with SLE from the EBMT/EULAR registry included 17 children; all patients received autologous HSCT, mostly PBSCs, with about half of the products being unmanipulated; there was a 55% DFS at 60 months post transplant, with 12% TRM. 64 Vonk et al. reported on the results of 26 patients with systemic sclerosis, 5 of whom were children, who received autologous HSCT; it is noted that 3 of the 5 children were in CR at 13-67 months post transplant, with either cyclophosphamide alone or Cyclophosphamide/ALG conditioning, and there was no TRM among the children of the cohort. 65 Finally, a study of 36 patients with refractory cytopenias (27 autologous transplants and 9 allogeneic transplants) included at least one child less than 21 years in each group. Although their outcomes are not reported independently, at 48 months post transplant, there were 9 PRs or CRs in the autologous group; 6 had transient responses, and there were 4 patients with TRM. In the allogeneic group, there were 5 CRs, with one transient response and one case of TRM, 66 further supporting the advantage of allogeneic over autologous transplant in another autoimmune condition. Two other case reports are noteworthy: a 7-year-old female who received a matched sibling transplant for congenital dyserythropoietic anemia after conditioning with Busulfan, Cyclophosphamide and ATG was cured of her coincident familial Mediterranean fever, 67 and one patient with immune mediated hemolytic anemia that relapsed after autologous PBSCT was cured after allogeneic transplant with Busulfan, Thiotepa, Fludarabine and ALG conditioning. 68 Taken together with Passweg et al.'s data 66 and the summarized data above, these data suggest an advantage for an allogeneic approach in the setting of autoimmune disease taking into account the small numbers of patients who have received allogeneic transplants. In addition, the consideration of GVHD and the balance between GVH and GVA is in some ways even more complex than that between GVHD and GVL/T. It is difficult to imagine putting a patient through an already risky procedure, which, if successful, carries with it a more than 50% chance of substituting one autoimmune disease for another. 69 
Unanswered questions
With the dearth of existing data, their heterogeneous nature, and the inclusion of results of HSCT in children within larger reports of adults, many questions remain in addition to the essential one as to whether the benefit of HSCT outweighs its risks in the setting of pediatric autoimmune disease. What conditioning regimen should be used? Certainly, adult data support the use of nonmyeloablative regimens with lower TRM, but are certain agents to be avoided? The correlation of higher doses of Busulfan with post transplant MAS is one example of the importance of tailoring conditioning in this patient population. It is also very likely that the same preparative regimen may not be ideal for different autoimmune diseases. Is in vivo or in vitro T cell depletion desired, as initially assumed, or are donor T cells necessary for eradication of autoreactive recipient lymphocytes? On a similar note, is GVHD to be avoided, as is the usual practice in the non-malignant setting, or does its obviation go hand in hand with decreased GVA? Is there truly a benefit to allogeneic transplant, or can autoimmune diseases be treated just as well with 'safer' autologous transplantation? (Table 3) .
These questions are anything but novel when considering HSCT in any patient; they are more salient in the context of transplant for autoimmune disease. Mortality rates overall are reported to be 2-4%. 70 Similarly, SLE has a 10% 10-year mortality rate, 71 and those who do not die from their disease have significant morbidity from organ involvement, especially renal disease. 72 Five-year mortality rates for children with systemic sclerosis who have severe organ involvement are 9%. 73 Survivors, especially those requiring ongoing treatment, carry with them lifelong burdens from the diseases and their treatments. 3 Although the hematology/oncology community is willing to 'tolerate' a degree of accelerated TRM with transplantation in the setting of diseases that are ultimately lethal, 69, [74] [75] [76] the rheumatology community is generally dealing with diseases where the short-term risk of mortality is less than that of a 'standard' myeloablative transplant and where the long-term outcomes of conventionally treated patients may be quite variable. These concerns become even more heightened when allogeneic transplants are considered. The specter of chronic GVHD after allogeneic transplantation is often interpreted as substituting one autoimmune disease with another. 69 There is an even less acceptable risk in patients who survive their immediate transplant but have relapse of their primary disease in the setting of full donor chimerism. 50 Finally, given the real risks of treatment-related morbidity and mortality associated with HSCT, the consideration of HSCT in patients with autoimmune disease is perpetually delayed as newer biologic agents such as TNF antagonists, costimulation blockers, cytokine inhibitors, and the like (reviewed in Moss and Isenberg 77 ) are introduced to the community on a regular basis. 78 Many of the 5-10% of patients with active JIA who are refractory to conventional therapies are refractory to these new biologic agents as well. 43 These agents are often used off-label in children and have side effects and toxicities of their own, many of which are as yet unknown in children. Their use is generally associated with less serious risks than transplant, and as such are used as third-line agents when immunosuppressants and low dose chemotherapy have failed.
Conclusions
The rheumatology community recognizes the need for ongoing clinical trials in this area, yet is also acutely aware of the obstacles to such research. Having established the Pediatric Rheumatology Collaborative Study Group and the Pediatric Rheumatology International Trials Organization, they have made great strides in the treatment and standardization of diagnosis and response evaluation to conventional and biologic therapy in this field. 3 Likewise, the studies of HSCT for autoimmune disease in pediatrics will move forward only if there is a collaborative effort among experts in both the rheumatology and HSCT disciplines undertaking randomized clinical trials in the subgroup of patients with refractory autoimmune disease.
Although the data are sparse, what has been published thus far, in conjunction with promising adult data, seems to provide a solid foundation for a pilot trial evaluating auto vs allo HSCT in children who have a matched related donor or cord blood unit available. Given the constant availability of new biologics on the horizon, a potential trial could look at transplant options in patients who have failed biologic therapy, or even in conjunction with it. Further, these cooperative efforts must include biology and biomarker studies in an attempt to discern and analyze clinical and laboratory factors that correlate with patient outcomes. Only with this framework in place will we have the ability to systematically and critically evaluate the role of stem cell transplantation in refractory autoimmune disease. Table 3 Unanswered questions with regard to utility/safety of HSCT in pediatric autoimmune disease
Timing of transplant
As salvage therapy when all other therapies have failed? As upfront therapy for patients with high-risk disease? 
